首页|MRI肝脏影像报告和数据系统对非肝硬化乙肝患者肝细胞癌的诊断价值

MRI肝脏影像报告和数据系统对非肝硬化乙肝患者肝细胞癌的诊断价值

Diagnostic value of MRI Liver Image Reporting and Data System (LI-RADS) for hepatocellular carcinoma in patients with non-cirrhotic hepatitis B

扫码查看
目的:探讨MRI肝脏影像报告和数据系统(LI-RADS)对非肝硬化乙型病毒性肝炎(乙肝)患者肝细胞癌(HCC)的诊断价值。方法:回顾性分析2015年12月至2018年5月在中山大学附属第三医院接受腹部MRI增强扫描检查,并经实验室检查及组织病理学检查证实为无肝硬化的慢性乙肝患者161例临床资料。其中男127例,女34例;年龄28~71岁,中位年龄49岁。本研究经我院伦理委员会批准,免除了知情同意要求。由2名放射科医师同时对161例患者MRI图像进行LI-RADS v2018分类,并达成共识得到病灶最终LI-RADS v2018诊断结果,将其与金标准比较,其中恶性病变以病理学结果为金标准,良性病变以临床和放射学随访至少2年的结果为金标准,计算LI-RADS v2018诊断HCC的敏感度、特异度、阳性预测值、阴性预测值、准确度。结果:161例患者161个病灶,其中HCC病灶71个,非HCC恶性肿瘤23个,良性病变67个。最终138个病灶经病理诊断证实,23例通过临床和随访MRI图像证实。MRI强化特征中,非环形动脉期强化占67.1%(108/161),弥散受限占83.9%(135/161),稍高T2WI信号占80.1%(129/161)。LI-RADS分类为LR-1、LR-2、LR-3、LR-4、LR-5和LR-M的病灶数分别为6、43、15、12、70、15例。LR-5中,HCC 64例,非HCC的恶性肿瘤5例,肝腺瘤1例。LR-5诊断HCC的敏感度、特异度、阳性预测值、阴性预测值和准确度分别为0.901、0.933、0.914、0.923和91.2%。LR-M中,HCC 4例,非HCC的恶性肿瘤11例。结论:MRI增强检查LI-RADS v2018评价体系对非肝硬化乙肝患者HCC的诊断具有较高的诊断价值,包括高敏感度、特异度、阳性预测值、阴性预测值和准确度。
Objective:To evaluate the diagnostic value of MRI Liver Image Reporting and Data System (LI-RADS) for hepatocellular carcinoma (HCC) in patients with non-cirrhotic hepatitis B.Methods:Clinical data of 161 patients who were diagnosed with non-cirrhotic chronic hepatitis B by laboratory and histopathological examination and received enhanced abdominal MRI scanning in the Third Affiliated Hospital of Sun Yat-sen University from December 2015 to December 2018 were retrospectively analyzed. Among them, 127 patients were male and 34 female, aged from 28 to 71 years, with a median age of 49 years. This study was approved by the ethical committee of our hospital, and the requirement of informed consent was exempted. MRI images of 161 patients were simultaneously classified according to LI-RADS v2018 by two radiologists. A consensus was reached to obtain the final diagnostic result of LI-RADS v2018, which was compared with the gold standard. Pathological results were regarded as the gold standard for malignant lesions and the results of clinical and radiological follow-up for at least 2 years were considered as the gold standard for benign lesions. The sensitivity, specificity, positive predictive value, negative predictive value and accuracy ofLI-RADS v2018 in diagnosing HCC were calculated.Results:There were 161 lesions in 161 patients, including 71 HCC lesions, 23 non-HCC malignant tumors and 67 benign lesions. 138 lesions were finally diagnosed by pathological examination, and 23 cases were confirmed by clinical and MRI images during follow-up. Among MRI enhancement features, non-circular enhancement in arterial phase accounted for 67.1% (108/161), 83.9% (135/161) for diffusion limitation and 80.1% (129/161) for slightly high T2WI signal, respectively. 6, 43, 15, 12, 70 and 15 lesions were classified as LR-1, LR-2, LR-3, LR-4, LR-5 and LR-M by LI-RADS, respectively. There were 64 cases of HCC, 5 cases of non-HCC malignant tumors and 1 case of hepatic adenoma in LR-5. The sensitivity, specificity, positive predictive value, negative predictive value and accuracy of LR-5 in diagnosing HCC were 0.901, 0.933, 0.914, 0.923 and 91.2%, respectively. In LR-M, 4 cases were HCC and 11 cases were non-HCC malignant tumors.Conclusions:Enhanced MRILI-RADS evaluation system has high diagnostic value for HCC in patients with non-cirrhotic hepatitis B, which yields high sensitivity, specificity, positive predictive value, negative predictive value and accuracy.

韩宇、张武、李安琪、陈文颖、谢斯栋

展开 >

510630 广州,中山大学附属第三医院放射科

癌,肝细胞 磁共振成像 肝脏影像报告和数据成像系统 非肝硬化

2023

中华肝脏外科手术学电子杂志
中华医学会

中华肝脏外科手术学电子杂志

CSTPCD
影响因子:0.822
ISSN:2095-3232
年,卷(期):2023.12(6)
  • 3